Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Scilex Holding Company ( (SCLX) ) is now available.
On August 16, 2025, Jaisim Shah resigned as CEO and President of Scilex Holding Company to focus on Semnur Pharmaceuticals, a majority-owned subsidiary, and its development of SP-102. Henry Ji, Ph.D., was appointed as the new CEO and President of Scilex. The company also announced a $20 million private placement agreement for Semnur to advance SP-102’s clinical trials, highlighting the strategic focus on non-opioid pain management and the potential value unlocking for Semnur as it transitions to a public company.
The most recent analyst rating on (SCLX) stock is a Buy with a $770.00 price target. To see the full list of analyst forecasts on Scilex Holding Company stock, see the SCLX Stock Forecast page.
More about Scilex Holding Company
Scilex Holding Company is a revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases. The company targets indications with high unmet needs and large market opportunities, offering products such as ZTlido, ELYXYB, and Gloperba, and has several product candidates in development.
Average Trading Volume: 194,475
Technical Sentiment Signal: Hold
Current Market Cap: $124.9M
Find detailed analytics on SCLX stock on TipRanks’ Stock Analysis page.